Poxel SA (FR:POXEL)
:POXEL
Top Page
Poxel SA
(POXEL)
Select Model
Select Model
Rating:46Neutral
Price Target:
€0.37
▲(62.17% Upside)
Action:ReiteratedDate:02/03/26
The score is primarily constrained by weak financial performance—persistent losses, negative operating cash flow, and a highly stressed balance sheet with negative equity and rising debt. Technicals provide some support via recent upward momentum, but near-overbought readings add risk. Valuation remains challenged due to ongoing losses and no dividend information.
Positive Factors
Commercial partnership with Sumitomo Pharma
A revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.
Negative Factors
Highly stressed balance sheet
Deep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial partnership with Sumitomo Pharma
A revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.
Read all positive factors
Poxel SA (POXEL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€12.65M
Dividend YieldN/A
Average Volume (3M)288.32K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees6
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,758,167
10 Day Avg. Volume262,495
30 Day Avg. Volume288,318
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Poxel SA Business Overview & Revenue Model
Company Description
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical deve...
How the Company Makes Money
Poxel makes money primarily through (1) product-related income from TWYMEEG (imeglimin) in Japan via its partnership with Sumitomo Pharma—this has historically included milestone payments and other collaboration-related receipts tied to developmen...
Poxel SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.66M | 6.64M | 1.98M | 674.00K | 13.40M | 6.81M |
| Gross Profit | 3.95M | 3.66M | 1.00K | 2.00K | 13.34M | 6.81M |
| EBITDA | -3.07M | -4.32M | -12.17M | -28.02M | -22.52M | -29.71M |
| Net Income | -13.66M | -18.30M | -35.09M | -31.40M | -23.76M | -31.86M |
Balance Sheet | ||||||
| Total Assets | 5.00M | 14.93M | 4.82M | 34.71M | 54.89M | 65.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.06M | 3.66M | 2.34M | 13.06M | 32.29M | 40.20M |
| Total Debt | 60.99M | 69.71M | 47.03M | 43.44M | 35.14M | 23.62M |
| Total Liabilities | 66.41M | 73.87M | 53.90M | 52.95M | 46.68M | 38.20M |
| Stockholders Equity | -61.40M | -58.94M | -49.10M | -18.24M | 8.21M | 27.07M |
Cash Flow | ||||||
| Free Cash Flow | 7.54M | 0.00 | 3.05M | -21.84M | -16.94M | -26.03M |
| Operating Cash Flow | -7.21M | -17.61M | -13.98M | -21.81M | -16.89M | -25.75M |
| Investing Cash Flow | 28.00K | 92.00K | 41.00K | -5.00K | -42.00K | 52.00K |
| Financing Cash Flow | 6.43M | 18.82M | 3.23M | 2.58M | 9.03M | 28.71M |
Poxel SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €130.87M | -24.25 | -85.59% | ― | -10.91% | -25.57% | |
48 Neutral | €23.88M | -1.75 | ― | ― | ― | ― | |
48 Neutral | €43.60M | -2.27 | ― | ― | ― | 10.30% | |
47 Neutral | €22.88M | -2.40 | ― | ― | 101.95% | 35.55% | |
46 Neutral | €12.65M | -2.41 | ― | ― | ― | ― |
* General Sector Average
FR:POXEL
Poxel SA
0.24
-0.03
-11.99%
FR:ALCOX
Nicox SA
0.40
0.14
56.25%
FR:ABNX
ABIONYX Pharma SA
3.72
2.45
192.52%
FR:ALDVI
Advicenne SA
1.57
0.07
5.01%
FR:ALVAL
Valbiotis SA
1.01
-0.04
-3.54%
FR:ALTHX
Theranexus SA
3.02
2.61
631.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.